In agreement, costs involved absolutely manouth. Cost savings down the road also humongous. I guess we need that first hurdle before we consider running for first place. A thought that may have been discussed.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025